CoreCap Advisors
TVTX icon

CoreCap Advisors’s Travere Therapeutics TVTX Stock Holding History

CoreCap Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.24K Hold
21
– – ﹤0.01% 2624
2026
Q2 		$1.19K Hold
21
– – ﹤0.01% 2658
2026
Q1 		$624 Hold
21
– – ﹤0.01% 2615
2025
Q4 		$802 Buy
+21
New +$683 ﹤0.01% 2630

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Insight Wealth Strategies
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
OpenArc Corporate Advisory
OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CoreCap Advisors's TVTX Position: Q3 2026 in Review

CoreCap Advisors held its Travere Therapeutics (TVTX) position steady in Q3 2026 at 21 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #2624.

CoreCap Advisors first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. 33 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • CoreCap Advisors held 21 shares of Travere Therapeutics worth $1.24K as of Q3 2026.
  • CoreCap Advisors left its Travere Therapeutics share count unchanged in Q3 2026.
  • Travere Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2624 holding.
  • CoreCap Advisors first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 33 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.